Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Very Bullish +85

Gene Therapy Briefs: Regeneron Wins FDA Approval for First Neurosensory Gene Therapy

AI-generated analysis

πŸ† Regeneron has secured FDA accelerated approval for Otarmeni, marking it as the first gene therapy to restore neurosensory function in humans.

πŸ‘‚ Otarmeni targets severe-to-profound sensorineural hearing loss caused by specific OTOF gene variants and requires preserved outer hair cell function.

πŸ’Š The therapy uses an adeno-associated virus vector and is administered via a single intracochlear infusion dose.

❀️ Regeneron announced that Otarmeni will be made available free of charge to patients in the U.S. market.

πŸ“Š In the CHORD Phase I/II trial, 80% of participants achieved hearing sensitivity improvements at ≀70 dB HL by week 24.

🧠 Additional data showed that 42% of all participants followed for 48 weeks achieved normal hearing levels including whispers.

βš™οΈ The FDA approval is pending verification of clinical benefits in the confirmatory portion of the CHORD trial.

πŸ› This milestone makes Otarmeni the first gene therapy and second new molecular entity to receive a CNPV voucher for expedited review.

βœ‚οΈ Intellia Therapeutics has submitted a rolling Biologics License Application (BLA) for lonvo-z following positive Phase III HAELO trial data.

🦠 Lonvo-z utilizes CRISPR technology to permanently inactivate the KLKB1 gene, reducing kallikrein and bradykinin levels in hereditary angioedema patients.

πŸ“‰ In the HAELO trial, a single dose of lonvo-z reduced annual attack rates by 87% compared to placebo over a six-month period.

✨ Approximately 62% of patients treated with lonvo-z were entirely free from attacks and therapy needs during the observation window.

πŸ›‘οΈ Safety data indicated that all adverse events were mild or moderate with no serious adverse events observed in the treatment group.

πŸ“… Intellia plans to present additional clinical data from the HAELO trial at the 2026 European Academy of Allergy and Clinical Immunology Congress in Istanbul.

πŸ”¬ Lonvo-z is designed as a one-time curative treatment that eliminates the need for ongoing therapy for eligible patients with Type I or II HAE.

Bullish Signals
  • Regeneron Pharmaceuticals has secured FDA accelerated approval for Otarmeniβ„’ (lunsotogene parvec-cwha), marking the first gene therapy approved to restore neurosensory function, specifically for severe-to-profound sensorineural hearing loss.
  • The Phase I/II CHORD trial demonstrated that 80% of participants achieved primary endpoint improvement in hearing sensitivity at ≀70 dB HL within 24 weeks, with data showing sustained responses even through week 48.
  • Remarkably, among patients followed to 48 weeks, 42% (five of 12) achieved normal hearing including whispers (≀25 dB HL), and all prior responders maintained their therapy response.
  • Otarmeni is the first gene therapy to receive FDA approval under the Commissioner's National Priority Voucher (CNPV) pilot program, which entitles companies to expedited final reviews of 1–2 months compared to the standard 10–12 months.
  • Regeneron announced that Otarmeni will be made available for free in the U.S., providing a significant access advantage for qualifying patients with OTOF-related hearing loss.
  • Intellia Therapeutics launched its Biologics License Application (BLA) for lonvo-z following positive Phase III HAELO trial data, where the one-time gene editing treatment reduced HAE attacks by 87% versus placebo.
  • In the six-month efficacy evaluation period, 62% of patients in the lonvo-z arm were entirely attack free and therapy free, compared to only 11% in the placebo arm, with statistical significance of p<0.0001.
  • Lonvo-z demonstrated a favorable safety profile with all reported adverse events being mild or moderate and no serious adverse events observed, while remaining long-term prophylaxis free for all treated patients.
Risk Factors
  • Regeneron's Otarmeniβ„’ approval relies on an accelerated pathway, meaning future confirmatory data from the CHOIRD trial could potentially lead to withdrawal or additional labeling restrictions if outcomes do not sustain initial findings.
  • The pivotal Phase I/II CHORD trial involved only 20 participants across two dose cohorts, which is a relatively small sample size for establishing definitive long-term safety and efficacy compared to standard large-scale clinical trials.
  • Approximately 28% of the treated cohort (5 of 12) had not achieved the threshold for normal hearing (≀25 dB HL) by week 48 despite prior response, indicating variability in treatment outcome that may not be uniform across a broader patient population.
  • Regeneron will provide Otarmeni free of charge in the U.S., which may signal concerns about long-term commercial viability or reimbursement uncertainty in other global markets where regulatory approval and pricing models are less clear.
  • While no serious adverse events were observed in Intellia's HAELO trial, infusion-related reactions, headache, and fatigue remain the most common treatment emergent adverse events, which could impact patient quality of life and adherence to the one-time dose regimen.
Full Analysis
Regeneron Pharmaceuticals has secured FDA accelerated approval for Otarmeni, an adeno-associated virus vector-based gene therapy designed to restore neurosensory function in patients with severe-to-profound sensorineural hearing loss caused by biallelic variants in the OTOF gene. The therapy, previously known as DB-OTO, is indicated for children and adults aged 10 months to 16 years who have preserved outer hair cell function and no prior cochlear implantation in the affected ear. Regeneron announced that it will make the therapy available free of charge to patients in the United States. The approval was granted based on efficacy data from the Phase I/II CHORD clinical trial (NCT05788536), where hearing improvement was measured by average pure tone audiometry at week 24. In the trial involving 20 participants, 80% of patients achieved a hearing threshold of less than or equal to 70 decibels at 24 weeks, meeting the primary endpoint, and 70% achieved an auditory brainstem response threshold of less than or equal to 90 decibels. Among those followed to week 48, all prior responders maintained their improvement, and 42% of the total participants achieved normal hearing levels including whispers. Regulatory approval is contingent upon confirmation of these benefits in the larger confirmatory portion of the CHOIRD trial. Notably, Otarmeni represents the first gene therapy approved under the FDA's Commissioner's National Priority Voucher pilot program, which fast-tracks review times to 1–2 months for drugs addressing significant health crises or unmet public health needs. In a separate development highlighted within the same briefs section, Intellia Therapeutics has launched a rolling Biologics License Application (BLA) submission with the FDA for its crispr-based gene editing therapy, lonvoguran ziclumeran, also known as lonvo-z, for the treatment of hereditary angioedema. This decision follows positive topline results from the global Phase III HAELO trial, which enrolled 80 patients including those aged 16 and older with Type I or Type II HAE. The study met its primary endpoint by demonstrating that a single one-time infusion reduced HAE attacks by 87% compared to placebo over a six-month evaluation period from weeks 5 to 28. Patients treated with lonvo-z experienced a mean monthly attack rate of 0.26 versus 2.10 in the placebo group, and 62% were entirely free from attacks and therapy during that period compared to 11% for placebo. The therapy works by inactivating the KLKB1 gene to permanently lower kallikrein and bradykinin levels, offering a potential one-time cure for the condition. Lonvo-z demonstrated favorable safety and tolerability with only mild or moderate adverse events reported, and all patients remained long-term prophylaxis free as of the data cutoff on February 10, 2026. Further clinical data from the HAELO trial is scheduled to be presented at the 2026 European Academy of Allergy and Clinical Immunology Congress in Istanbul.